By Foo Yun Chee
BRUSSELS (Reuters) -Novo Holdings on Friday gained unconditional EU antitrust approval for its $16.5 bln acquisition of U.S. contract drug maker Catalent (NYSE:CTLT) after EU regulators stated they didn’t see any competitors points.
Novo Holdings, the controlling shareholder of Danish drugmaker Novo Nordisk (NYSE:NVO), which makes the blockbuster weight-loss drug Wegovy, stated it now expects to shut the deal by 12 months finish.
“The proposed merger wouldn’t elevate competitors issues on any of the markets examined within the EEA (European Financial Space) or on any substantial a part of it,” the European Fee stated in an announcement, confirming a Reuters story.
The EEA refers back to the 27 EU international locations, Iceland, Liechtenstein and Norway.
The EU antitrust watchdog stated there are adequate competing alternate options available in the market.
“With the European Fee’s approval, we’re one step nearer to delivering the advantages of this transaction,” stated Jonathan Levy, senior companion at Novo Holdings.
Hovering gross sales of Wegovy have made Novo Nordisk Europe’s most useful firm by market worth.
By Florence Tan SINGAPORE (Reuters) - Oil costs inched up in early commerce on Monday…
Inventory futures edged decrease forward of an enormous week of earnings reviews and macroeconomic information…
A model of this put up first appeared on TKer.co We’ve been getting ambiguous alerts…
Two chairs of FTSE-100 firms are vying to succeed Adam Crozier on the prime of…
Shares rebounded over the previous week as feedback from President Trump eased investor issues about…
By David Lawder, Karin Strohecker, Andrea Shalal WASHINGTON (Reuters) -International finance leaders got here to…